A sore throat or pharyngitis is caused when a virus infects the area of the throat. Some of the most common causes of pharyngitis is viral infections such as the influenza and common cold. Acute pharyngitis is one of the most common condition, hence, there has been an increase in demand for
systematic treatment and medication. Drug manufacturers are also focusing on research and development of new drugs to treat pharyngitis without causing any side-effects. This Fact.MR report analyzes the expansion of global pharyngitis market till date, and provides key insights on the growth of the market during the forecast period, 2017-2026.
Clinical manifestations of pharyngitis at times encompass tonsillar exudates, fever, painful cervical adenopathy, ear pain and pharyngeal erythema. There has been prevalence of associated symptoms such as conjunctivitis, rhinorrhea, coughing, heada che and rash.
Given pharyngitis is usually caused by a viral infection or bacterial infection, over-the-counter treatments have gained traction. Over-the-counter treatments have enabled self-management, facilitating a quicker return to normalcy and curbing the pressure to use antibiotics. There have been evidences suggesting probiotics and xylitol can curb the recurrence of upper respiratory tract infections. According to a random controlled trial (RCT) published in Canadian Medical Association Journal (CMAJ), there were no considerable effect of either probiotics or xylitol on pharyngitis (sore throat) symptoms. The study is one of only a few that looks to develop new drugs to combat sore throat without causing side-effects.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=361
Viral infections of the throat are not normally cultured owing to the mild self-limiting nature of the disease and the cost involved in the culturing the pathogens. There are fewer incidences of bacterial infections of the throat—vis-à-vis viral pharyngitis—however, delaying treatment of S pyogenes have led to patient’s chance of developing rheumatic fever. Accordingly, manufacturers are focusing on strategies for diagnosis of acute pharyngitis infections.
Group A strep infection, caused by S pyogenes may also affect patients with scarlet fever, according to CDC. Diagnosis with respect to acute pharyngitis incorporates multiple viral and bacterial pathogens. As such, clinicians vie to use either a rapid antigen detection test (RADT) or throat culture to confirm group A strep pharyngitis.
Pharyngitis Market: Overview
The report offers a coherent analysis on the pharyngitis market for the forecast period 2018-2026. Further, the report also shed light on dynamics of the market, including drivers, trends, restraints and opportunities. Besides, the report delves into the segmentation of the market which is aimed at providing readers with an in-depth view of the market.
Beta Lactams to Emerge as the Most-Preferred Drug Class
Compared to the various drug class, beta lactams is likely to emerge as one of the most preferred drug class between 2017 and 2026. Beta lactams is projected to bring in nearly US$ 500 million revenue by 2026 end. Beta-lactams include cephalosporins and penicillins. These drugs are active against many harmful organisms. Moreover, the recent development of broad-spectrum beta-lactams antibiotics active against gram-negative organisms has increased their use.
The market for pharyngitis adopts supply-demand approach to provide a holistic picture of the market. In-house panel of experts have thoroughly analyzed the research sources, including secondary sources and primary sources. Revenue comparison, market share comparison and Y-o-Y growth comparison on the geography lead to the market size of the pharyngitis. The growth of manufacturers in the historical and forecast period are estimated to assist the readers with investment decisions.
Pharyngitis Market: Competitive Landscape
Leading players being instrumental for the growth of the pharyngitis market are assessed and profiled with respect to financial overview, company overview, product offering, strategies, recent development and key differentiators. Furthermore, the report encompasses SWOT analysis to present an overall picture of the competitive landscape of the pharyngitis market.
Profiled companies that are expected to remain active in the expansion of global pharyngitis market through 2026, which include Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, BioStar Pharmaceuticals, Inc., and Zambon Group SpA.
systematic treatment and medication. Drug manufacturers are also focusing on research and development of new drugs to treat pharyngitis without causing any side-effects. This Fact.MR report analyzes the expansion of global pharyngitis market till date, and provides key insights on the growth of the market during the forecast period, 2017-2026.
Clinical manifestations of pharyngitis at times encompass tonsillar exudates, fever, painful cervical adenopathy, ear pain and pharyngeal erythema. There has been prevalence of associated symptoms such as conjunctivitis, rhinorrhea, coughing, heada che and rash.
Given pharyngitis is usually caused by a viral infection or bacterial infection, over-the-counter treatments have gained traction. Over-the-counter treatments have enabled self-management, facilitating a quicker return to normalcy and curbing the pressure to use antibiotics. There have been evidences suggesting probiotics and xylitol can curb the recurrence of upper respiratory tract infections. According to a random controlled trial (RCT) published in Canadian Medical Association Journal (CMAJ), there were no considerable effect of either probiotics or xylitol on pharyngitis (sore throat) symptoms. The study is one of only a few that looks to develop new drugs to combat sore throat without causing side-effects.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=361
Viral infections of the throat are not normally cultured owing to the mild self-limiting nature of the disease and the cost involved in the culturing the pathogens. There are fewer incidences of bacterial infections of the throat—vis-à-vis viral pharyngitis—however, delaying treatment of S pyogenes have led to patient’s chance of developing rheumatic fever. Accordingly, manufacturers are focusing on strategies for diagnosis of acute pharyngitis infections.
Group A strep infection, caused by S pyogenes may also affect patients with scarlet fever, according to CDC. Diagnosis with respect to acute pharyngitis incorporates multiple viral and bacterial pathogens. As such, clinicians vie to use either a rapid antigen detection test (RADT) or throat culture to confirm group A strep pharyngitis.
Pharyngitis Market: Overview
The report offers a coherent analysis on the pharyngitis market for the forecast period 2018-2026. Further, the report also shed light on dynamics of the market, including drivers, trends, restraints and opportunities. Besides, the report delves into the segmentation of the market which is aimed at providing readers with an in-depth view of the market.
Beta Lactams to Emerge as the Most-Preferred Drug Class
Compared to the various drug class, beta lactams is likely to emerge as one of the most preferred drug class between 2017 and 2026. Beta lactams is projected to bring in nearly US$ 500 million revenue by 2026 end. Beta-lactams include cephalosporins and penicillins. These drugs are active against many harmful organisms. Moreover, the recent development of broad-spectrum beta-lactams antibiotics active against gram-negative organisms has increased their use.
The market for pharyngitis adopts supply-demand approach to provide a holistic picture of the market. In-house panel of experts have thoroughly analyzed the research sources, including secondary sources and primary sources. Revenue comparison, market share comparison and Y-o-Y growth comparison on the geography lead to the market size of the pharyngitis. The growth of manufacturers in the historical and forecast period are estimated to assist the readers with investment decisions.
Pharyngitis Market: Competitive Landscape
Leading players being instrumental for the growth of the pharyngitis market are assessed and profiled with respect to financial overview, company overview, product offering, strategies, recent development and key differentiators. Furthermore, the report encompasses SWOT analysis to present an overall picture of the competitive landscape of the pharyngitis market.
Profiled companies that are expected to remain active in the expansion of global pharyngitis market through 2026, which include Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, BioStar Pharmaceuticals, Inc., and Zambon Group SpA.
Comments
Post a Comment